| |
MARKETWATCH
Authorized Generic Drugs, Price Competition, And Consumers Welfare
Ernst R. Berndt,
Richard Mortimer,
Ashoke Bhattacharjya,
Andrew Parece and
Edward Tuttle
The growing frequency of authorized generics has important implications for the welfare of prescription drug consumers. Authorized generic entry could affect the timing of generic entry, brand-name and generic prices, and generic penetration. We reviewed 1999–2003 data and found that generic entry in the absence of short-run exclusivity restrictions benefits consumers through lower short-run prices. We suggest that these benefits likely also result from authorized generics. We posit that long-run prices and shares are likely essentially unaffected by authorized generics and that potential costs to consumers from any delayed generic entry are likely small.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Higgins and S. J. H. Graham
Balancing Innovation and Access: Patent Challenges Tip the Scales
Science,
October 16, 2009;
326(5951):
370 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Aitken, E. R. Berndt, and D. M. Cutler
Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
Health Aff.,
January 1, 2009;
28(1):
w151 - w160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. G. Grabowski and J. L. Moe
Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention
Cancer Prevention Research,
July 1, 2008;
1(2):
84 - 90.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Comments:
Read all Comments
- No Proper Definitions Of Authorized Generics
- Manthan D. Janodia, et al.
- Health Affairs, 14 May 2007
[Full text]
- Authorized Generics And Their Effects On The Pharmaceutical Market
- Mangesh M. Chitrivekar
- Health Affairs, 22 May 2007
[Full text]
|